Hypertriglyceridemia Clinical Trial
Official title:
Phase 3, Multi-Site, Double-Blind, Randomized, Forced Titration, Parallel Group Evaluation Of The Efficacy, Safety, And Tolerability Of Fixed Combination Torcetrapib (CP 529,414)/Atorvastatin Administered Orally, Once Daily (Qd) For Eighteen Weeks, Compared With Atorvastatin Alone, In Subjects With Fredrickson Type IV Hypertriglyceridemia
Verified date | March 2007 |
Source | Pfizer |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Food and Drug Administration |
Study type | Interventional |
The Torcetrapib project was terminated on December 2, 2006 due to safety findings.
To assess the safety and efficacy of the fixed combination torcetrapib/atorvastatin in
subjects with Fredrickson Type IV Hypertriglyceridemia.
Status | Completed |
Enrollment | 160 |
Est. completion date | November 2006 |
Est. primary completion date | |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Diagnosis of Fredrickson Type IV Hypertriglyceridemia Exclusion Criteria: - Women who are pregnant or lactating, or planning to become pregnant. - Subjects with a clinically indicated need for statin (HMG-CoA reductase inhibitor) therapy other than atorvastatin or other concomitant therapy with known lipid altering effects on LDL-C and HDL-C including fibrates and nicotinic acid - Subjects taking any drugs known to be associated with an increased risk of myositis in combination with HMG-CoA reductase inhibitors - Subjects with any other medical condition or laboratory abnormality which could affect subject safety, preclude evaluation of response, or render unlikely that the subject would complete the study |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Canada | Pfizer Investigational Site | Chicoutimi | Quebec |
Canada | Pfizer Investigational Site | Halifax | Nova Scotia |
Canada | Pfizer Investigational Site | London | Ontario |
Canada | Pfizer Investigational Site | Montreal | Quebec |
Canada | Pfizer Investigational Site | Ste-Foy | Quebec |
United States | Pfizer Investigational Site | Anaheim | California |
United States | Pfizer Investigational Site | Ann Arbor | Michigan |
United States | Pfizer Investigational Site | Baton Rouge | Louisiana |
United States | Pfizer Investigational Site | Bethesda | Maryland |
United States | Pfizer Investigational Site | Canton | Michigan |
United States | Pfizer Investigational Site | Chicago | Illinois |
United States | Pfizer Investigational Site | Farmington | Connecticut |
United States | Pfizer Investigational Site | Hollywood | Florida |
United States | Pfizer Investigational Site | Huntington Beach | California |
United States | Pfizer Investigational Site | Indianapolis | Indiana |
United States | Pfizer Investigational Site | Jefferson City | Missouri |
United States | Pfizer Investigational Site | Las Vegas | Nevada |
United States | Pfizer Investigational Site | Longwood | Florida |
United States | Pfizer Investigational Site | Los Angeles | California |
United States | Pfizer Investigational Site | Madison | Wisconsin |
United States | Pfizer Investigational Site | Olive Branch | Mississippi |
United States | Pfizer Investigational Site | Orange | California |
United States | Pfizer Investigational Site | Orangevale | California |
United States | Pfizer Investigational Site | Overland Park | Kansas |
United States | Pfizer Investigational Site | Pacific Palisades | California |
United States | Pfizer Investigational Site | Portage | Michigan |
United States | Pfizer Investigational Site | Richland | Michigan |
United States | Pfizer Investigational Site | Richmond | Virginia |
United States | Pfizer Investigational Site | Rochester | New York |
United States | Pfizer Investigational Site | San Antonio | Texas |
United States | Pfizer Investigational Site | Scarborough | Maine |
United States | Pfizer Investigational Site | Sellersville | Pennsylvania |
United States | Pfizer Investigational Site | St. Cloud | Minnesota |
United States | Pfizer Investigational Site | St. Louis | Missouri |
United States | Pfizer Investigational Site | Statesville | North Carolina |
United States | Pfizer Investigational Site | Studio City | California |
United States | Pfizer Investigational Site | Syracuse | New York |
United States | Pfizer Investigational Site | Tripler AMC | Hawaii |
United States | Pfizer Investigational Site | Tustin | California |
United States | Pfizer Investigational Site | Walnut Creek | California |
United States | Pfizer Investigational Site | Warwick | Rhode Island |
United States | Pfizer Investigational Site | Washington | District of Columbia |
United States | Pfizer Investigational Site | West Palm Beach | Florida |
United States | Pfizer Investigational Site | West Seneca | New York |
Lead Sponsor | Collaborator |
---|---|
Pfizer |
United States, Canada,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in HDL-C and non-HDL-C levels | |||
Secondary | Changes in levels of other lipid and biomarkers. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03929198 -
Translation of Pritikin Program to the Community
|
N/A | |
Completed |
NCT02250105 -
Trial of ARI-3037MO to Reduce Triglyceride Levels in Adults With Severe (≥500 mg/dl) Hypertriglyceridemia
|
Phase 2 | |
Completed |
NCT02859129 -
Study to Evaluate the 2-Way Interaction Between Multiple Doses of Epanova™ and a Single Dose of Rosuvastatin (Crestor®)
|
Phase 1 | |
Completed |
NCT01455844 -
TRIal For Efficacy of Capre on hyperTriglyceridemiA
|
Phase 2 | |
Completed |
NCT01437930 -
Intervention With n-3 Polyunsaturated Fatty Acids (PUFA)-Supplemented Products in Moderate Hypertriglyceridemic Patients
|
N/A | |
Completed |
NCT00959842 -
Effects of Lovaza on Lipoprotein Composition and Function in Mild Hypertriglyceridemia
|
Phase 1/Phase 2 | |
Completed |
NCT01010399 -
Boosted Lexiva With Lovaza Adjunctive Therapy in Hypertriglyceridemic, HIV-Infected Subjects
|
Phase 4 | |
Completed |
NCT00519714 -
A Study to Evaluate the Lipid Regulating Effects of 1-Methylnicotinamide (1-MNA)
|
Phase 2/Phase 3 | |
Recruiting |
NCT00186537 -
Comparing Tricor, Avandia, or Weight Loss to Lower Cardiovascular Risk Factors in People With High Triglycerides.
|
N/A | |
Completed |
NCT00246402 -
Acipimox to Improve Hyperlipidemia and Insulin Sensitivity Associated With HIV
|
N/A | |
Completed |
NCT06020950 -
Chia Seeds Consumption in Hypertriglyceridemia
|
N/A | |
Completed |
NCT02354976 -
A Double-blind Randomized Placebo-controlled Study Comparing Epanova and Fenofibrate on Liver Fat in Overweight Subjects.
|
Phase 2 | |
Completed |
NCT04966494 -
Impact of Beans and Oats Snack Bar on Hypertriglyceridemic Women
|
N/A | |
Completed |
NCT04650152 -
Study to Assess Tricor Therapy Effectiveness in Patients With Metabolic Syndrome (TRISTAN)
|
||
Completed |
NCT04630366 -
A Phase 1, First Time in Humans Study of NST-1024
|
Phase 1 | |
Completed |
NCT03693131 -
Efficacy of MND-2119 in Participants With Hypertriglyceridemia
|
Phase 3 | |
Completed |
NCT04756180 -
An Efficacy and Safety Study of Omega-3-acid Ethyl Ester in Chinese Subjects With Hypertriglyceridemia.
|
Phase 3 | |
Completed |
NCT02868177 -
Effect of Totum-63, Active Ingredient of Valedia, on Glucose and Lipid Homeostasis on Subjects With Prediabetes
|
Phase 2/Phase 3 | |
Completed |
NCT01968720 -
Pilot Study To Assess CAT-2003 in Patients With Severe Hypertriglyceridemia
|
Phase 2 | |
Completed |
NCT01462877 -
A Study to Evaluate Fenofibrate Combination With Statin in Chinese Patients With Dyslipidemic
|
Phase 4 |